Aurobindo Pharma Reports Positive Phase 3 Results for Omalizumab Biosimilar BP11 06/04/2026 / Business Updates / R&D / Product Development Aurobindo Pharma Reports Positive Phase 3 Results for Omalizumab Biosimilar BP11 Read Post ยป
